You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ruxolitinib

Showing 51 - 75 of 181
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Graft-versus-host-disease, Stem Cell Transplant Complications, Acute Myeloid Leukemia Trial in Moscow, Saint Petersburg

Recruiting
  • Graft-versus-host-disease
  • +3 more
  • Ruxolitinib
  • +2 more
  • Moscow, Russian Federation
  • +1 more
Apr 4, 2022

aGVHD, Stem Cell Transplant Complications Trial in Beijing (Ruxolitinib, Corticosteroid)

Recruiting
  • aGVHD
  • Stem Cell Transplant Complications
  • Beijing, Beijing, China
    Chinese PLA General Hospital
May 23, 2022

Myeloproliferative Tumors Trial in Worldwide (INCA033989, Ruxolitinib)

Recruiting
  • Myeloproliferative Neoplasms
  • Herston, Queensland, Australia
  • +22 more
Jun 30, 2023

COVID-19 Trial (Ruxolitinib)

No longer available
  • COVID-19
  • Ruxolitinib
  • (no location specified)
Dec 1, 2021

T-cell Lymphomas, NK-Cell Lymphomas Trial in United States (Ruxolitinib, Duvelisib)

Recruiting
  • T-cell Lymphomas
  • NK-Cell Lymphomas
  • Miami, Florida
  • +8 more
Aug 1, 2022

Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF), Thrombocythemia Myelofibrosis (PET-MF) Trial

Available
  • Primary Myelofibrosis (PMF)
  • +2 more
  • Ruxolitinib
  • (no location specified)
Jan 18, 2022

Hodgkin Lymphoma Trial in United States (Ruxolitinib, Nivolumab)

Recruiting
  • Hodgkin Lymphoma
  • Chicago, Illinois
  • +4 more
Feb 16, 2022

Transplant-Related Disorder Trial in Tianjin (Ruxolitinib)

Recruiting
  • Transplant-Related Disorder
  • Ruxolitinib
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jan 28, 2023

Hodgkin's Lymphoma, Lymphoma, Non-Hodgkin Trial in Ann Arbor (Bortezomib, Ruxolitinib)

Completed
  • Hodgkin's Lymphoma
  • Lymphoma, Non-Hodgkin
  • Ann Arbor, Michigan
    University of Michgan Comprehensive Cancer Center
Dec 3, 2021

Transplant-Related Disorder Trial (Ruxolitinib)

Not yet recruiting
  • Transplant-Related Disorder
  • Ruxolitinib
  • (no location specified)
Oct 25, 2022

Myelofibrosis Trial in Worldwide (PIM447, Ruxolitinib, LEE011)

Completed
  • Myelofibrosis
  • VIC, Melbourne, Australia
  • +8 more
Feb 7, 2022

Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome Trial in Seattle (Decitabine, Ruxolitinib,

Recruiting
  • Acute Myeloid Leukemia
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 18, 2022

Myelofibrosis (MF) Trial in Korea, Republic of, South Africa, United States (Mivebresib, Navitoclax, Ruxolitinib)

Active, not recruiting
  • Myelofibrosis (MF)
  • Stony Brook, New York
  • +6 more
Mar 23, 2022

Psoriasis Trial in United States (Ruxolitinib)

Completed
Has Results
  • Psoriasis
  • Ruxolitinib
  • Fridley, Minnesota
  • +3 more
Feb 4, 2022

Polycythemia Vera Trial in London, Oxford (Ruxolitinib, Hydroxycarbamide, Interferon-Alpha)

Recruiting
  • Polycythemia Vera
  • Ruxolitinib
  • +2 more
  • London, United Kingdom
  • +1 more
Nov 29, 2021

Other Cancer Trial in Boston (ruxolitinib)

Recruiting
  • Other Cancer
  • ruxolitinib
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 30, 2021

Cytokine Release Syndrome, COVID19 Trial in Greenville (Therapeutic Plasma Exchange, Ruxolitinib)

Completed
Has Results
  • Cytokine Release Syndrome
  • COVID19
  • Therapeutic Plasma Exchange
  • Ruxolitinib
  • Greenville, South Carolina
    Prisma Health
Nov 30, 2021

Myelofibrosis Trial in Gilbert, Houston (APG-1252, Ruxolitinib)

Withdrawn
  • Myelofibrosis
  • Gilbert, Arizona
  • +1 more
Jul 8, 2022

Myelofibrosis Trial in Worldwide (BMS-986158, Ruxolitinib, Fedratinib)

Recruiting
  • Myelofibrosis
  • La Jolla, California
  • +36 more
Jan 13, 2023

Eosinophilic Myeloid Tumor, Hypereosinophilic Syndrome Trial run by the National Institute of Allergy and Infectious Diseases

Recruiting
  • Eosinophilic Myeloid Neoplasm
  • Hypereosinophilic Syndrome
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

COVID-19, Pneumonia Trial in Toronto (Ruxolitinib)

Terminated
  • COVID-19
  • Pneumonia
  • Ruxolitinib
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Aug 13, 2021

Acute Lymphoblastic Leukemia, ALL, Childhood, ALL Trial in Chicago (Ruxolitinib, Cyclophosphamide, Cytarabine)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • Ruxolitinib
  • +12 more
  • Chicago, Illinois
    University of Chicago Medical Center
Sep 14, 2021

Accelerated/Blast-phase Myeloproliferative Tumor, Chronic-phase Myelofibrosis, IDH2 Mutation Trial in Canada, United States

Recruiting
  • Accelerated/Blast-phase Myeloproliferative Neoplasm
  • +2 more
  • Scottsdale, Arizona
  • +10 more
May 9, 2022

Primary Myelofibrosis, Secondary Myelofibrosis Trial in Duarte (procedure, drug, other)

Active, not recruiting
  • Primary Myelofibrosis
  • Secondary Myelofibrosis
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +9 more
  • Duarte, California
    City of Hope Medical Center
Nov 2, 2021

Steroid-Refractory Acute GVHD Trial in Worldwide (T-Guard, Ruxolitinib)

Terminated
  • Steroid-Refractory Acute Graft Versus Host Disease
  • Birmingham, Alabama
  • +47 more
Jan 22, 2023